Brief: TiumBio And Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial Of 'Merigolix For Uterine Fibroids
07/05/2025 14:44
May 7 (Reuters) - TiumBio Co Ltd 321550.KQ: TIUMBIO AND DAEWON PHARMACEUTICAL SUCCESSFULLY COMPLETE PHASE 2 CLINICAL TRIAL OF 'MERIGOLIX (TU2670/DW4902)' FOR UTERINE FIBROIDS TIUMBIO CO LTD - MERIGOLIX ACHIEVES PRIMARY ENDPOINT IN PHASE 2 TRIAL Source text: ID:nPn9VLm6Fa Further company coverage: 321550.KQ ((Reuters.Briefs@thomsonreuters.com;))
Recent news on TiumBio Co
See all newsBrief: TiumBio And Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial Of 'Merigolix For Uterine Fibroids
Brief: TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab
Brief: TiumBio Submits CTA For Phase 1b Clinical Trial Of TU7710
Brief: Tiumbio To Initiate Phase 2 Trial Of Tu2218 For Cancer
Brief: Tiumbio And Hansoh Pharma Announce Clinical Trial Approval Of 'HS-10518/TU2670' From NMPA In China